AstraZeneca Begins Production of Vaccine Specifically for Omicron Variant

[Photo by Reuters-Yonhap News]

[Asia Economy Reporter Byunghee Park] Multinational pharmaceutical company AstraZeneca, together with the University of Oxford in the UK, has started producing a vaccine to respond to the new COVID-19 variant Omicron, major foreign media reported on the 21st (local time).

AstraZeneca announced on the same day, "We have entered the preliminary stage of producing a vaccine to respond to the Omicron variant in collaboration with the University of Oxford."

Dr. Sandy Douglas, a researcher at Oxford University, also emphasized in an interview, "Adenovirus-based vaccines can theoretically respond quickly to any variant."

Unlike messenger RNA (mRNA) vaccines such as Pfizer and Moderna, the COVID-19 vaccine developed by AstraZeneca and Oxford University is adenovirus-based, using a chimpanzee adenovirus as a deoxyribonucleic acid (DNA) delivery vector.

This content was produced with the assistance of AI translation services.